Unicycive Therapeutics (UNCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $3.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason McCarthy has given his Buy rating due to a combination of factors including Unicycive Therapeutics’ strategic positioning and upcoming regulatory milestones. The company is gearing up for a significant event with the PDUFA date for oxylanthanum carbonate (OLC) set for June 28, 2025, which could lead to a commercial launch later in the year if approved. The recent Phase 2 study results have shown promising patient-reported outcomes, indicating improved adherence and satisfaction due to the therapy’s smaller tablet size and lower pill burden.
Additionally, the company’s financial health appears stable with a cash reserve that extends its operational runway into 2026. The valuation model incorporates a revenue risk adjustment and a discount rate to project a 12-month price target of $3.00, reflecting a favorable risk/reward profile. Unicycive’s focus on addressing key adherence barriers in kidney disease treatment positions it well for potential market success, contributing to the Buy rating.
In another report released on May 14, Guggenheim also maintained a Buy rating on the stock with a $6.00 price target.